why choose us

First received: November 24, 2022

Clinical Trial: 1-Year Follow-up of OPTIMA-5

Study Status: Active, not recruiting

Recruit Status: Active, not recruiting

Condition: ST-segment Elevation Myocardial Infarction (STEMI)

Study Type: Interventional


Official Title: A Single Bolus r-SAK Prior to Primary PCI for ST-elevation Myocardial Infarction (OPTIMA-5): 1-Year Follow-up

Brief Summary: The OPTIMA-5 trial is a prospective, multi-center, randomized, patient blinded, controlled trial comparing a single bolus of half-dose recombinant staphylokinase (r-SAK) with normal saline (NS) in patients with ST-segment elevation myocardial infarction (STEMI) presenting ?12 hours of symptom onset and expected to undergo primary percutaneous coronary intervention (PPCI) within 120 minutes. The results of OPTIMA-5 showed that a single bolus r-SAK prior to PPCI for STEMI improves infarct related artery (IRA)…

Read more